Retraction: A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5

Editorial Office, Frontiers

doi:10.3389/fphar.2025.1575621

RETRACTION article

Front. Pharmacol.

Sec. Inflammation Pharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1575621

Retraction: A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5

Provisionally accepted

Frontiers Editorial Office ^*

Frontiers Media SA, Lausanne, Switzerland

This article is a retraction of:

A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5
1. Read original article

The final, formatted version of the article will be published soon.

Please find the retraction notice below:Xin Z, Jin C, Chao L, Zheng Z, Liehu C, Panpan P, Weizong W, Xiao Z, Qingjie Z, Honggang H, Longjuan Q, Xiao C and Jiacan S (2018) A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5. Front. Pharmacol. 9:22. doi: 10.3389/fphar.2018.00022 “The publisher retracts the article cited above. Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors received a communication regarding the retraction and had a chance to respond. This communication has been recorded by the publisher. Frontiers would like to thank the users on PubPeer for bringing the published article to our attention.”

Keywords: RPS5, Matrine derivative, RANKL, Osteoclasts, AKT pathway

Received: 12 Feb 2025; Accepted: 12 Feb 2025.

Copyright: © 2025 Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Frontiers Editorial Office, Frontiers Media SA, Lausanne, Switzerland

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.